SEARCH

SEARCH BY CITATION

References

  • 1
    Southern PJ, Horbul JE, Miller BR, Maher DM: Coming of age: reconstruction of heterosexual HIV-1 transmission in human ex vivo organ culture systems. Mucosal Immunol 2011; 4:383396.
  • 2
    Nazli A, Chan O, Dobson-Belaire WN, Ouellet M, Tremblay MJ, Gray-Owen SD, Arsenault AL, Kaushic C: Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog 2010; 6:e1000852.
  • 3
    Saba E, Grivel JC, Vanpouille C, Brichacek B, Fitzgerald W, Margolis L, Lisco A: HIV-1 sexual transmission: early events of HIV-1 infection of human cervico-vaginal tissue in an optimized ex vivo model. Mucosal Immunol 2010; 3:280290.
  • 4
    Cole AM, Cole AL: Antimicrobial polypeptides are key anti-HIV-1 effector molecules of cervicovaginal host defense. Am J Reprod Immunol 2008; 59:2734.
  • 5
    Shapiro L, Pott GB, Ralston AH: Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1. FASEB J 2001; 15:115122.
  • 6
    Congote LF: Serpin A1 and CD91 as host instruments against HIV-1 infection: are extracellular antiviral peptides acting as intracellular messengers? Virus Res 2007; 125:119134.
  • 7
    Valore EV, Park CH, Igreti SL, Ganz T: Antimicrobial components of vaginal fluid. Am J Obstet Gynecol 2002; 187:561568.
  • 8
    Wira CR, Patel MV, Ghosh M, Mukura L, Fahey JV: Innate immunity in the human female reproductive tract: endocrine regulation of endogenous antimicrobial protection against HIV and other sexually transmitted infections. Am J Reprod Immunol 2011; 65:196211.
  • 9
    Horton RE, McLaren PJ, Fowke K, Kimani J, Ball TB: Cohorts for the study of HIV-1-exposed but uninfected individuals: benefits and limitations. J Infect Dis 2010; 202(Suppl 3):S377S381.
  • 10
    Burgener A, Boutilier J, Wachihi C, Kimani J, Carpenter M, Westmacott G, Cheng K, Ball TB, Plummer F: Identification of differentially expressed proteins in the cervical mucosa of HIV-1-resistant sex workers. J Proteome Res 2008; 7:44464454.
  • 11
    Iqbal SM, Ball TB, Levinson P, Maranan L, Jaoko W, Wachihi C, Pak BJ, Podust VN, Broliden K, Hirbod T, Kaul R, Plummer FA: Elevated elafin/trappin-2 in the female genital tract is associated with protection against HIV acquisition. AIDS 2009; 23:16691677.
  • 12
    Burgener A, Rahman S, Ahmad R, Lajoie J, Ramdahin S, Mesa C, Brunet S, Wachihi C, Kimani J, Fowke K, Carr S, Plummer F, Ball TB: Comprehensive proteomic study identifies serpin and cystatin antiproteases as novel correlates of HIV-1 resistance in the cervicovaginal mucosa of female sex workers. J Proteome Res 2011; 10:51395149.
  • 13
    Challacombe SJ, Sweet SP: Oral mucosal immunity and HIV infection: current status. Oral Dis 2002; 8(Suppl 2):5562.
  • 14
    Kopitar-Jerala N: The role of cystatins in cells of the immune system. FEBS Lett 2006; 580:62956301.
  • 15
    Mangan MS, Kaiserman D, Bird PI: The role of serpins in vertebrate immunity. Tissue Antigens 2008; 72:110.
  • 16
    Silverman GA, Whisstock JC, Bottomley SP, Huntington JA, Kaiserman D, Luke CJ, Pak SC, Reichhart JM, Bird PI: Serpins flex their muscle: I. Putting the clamps on proteolysis in diverse biological systems. J Biol Chem 2010; 285:2429924305.
  • 17
    Moreau T, Baranger K, Dadé S, Dallet-Choisy S, Guyot N, Zani ML: Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family. Biochimie 2008; 90:284295.
  • 18
    Bingle CD, Vyakarnam A: Novel innate immune functions of the whey acidic protein family. Trends Immunol 2008; 29:444453.
  • 19
    van Gent D, Sharp P, Morgan K, Kalsheker N: Serpins: structure, function and molecular evolution. Int J Biochem Cell Biol 2003; 35:15361547.
  • 20
    Whisstock JC, Silverman GA, Bird PI, Bottomley SP, Kaiserman D, Luke CJ, Pak SC, Reichhart JM, Huntington JA: Serpins flex their muscle: II. Structural insights into target peptidase recognition, polymerization, and transport functions. J Biol Chem 2010; 285:2430724312.
  • 21
    Ashton-Rickardt PG: Serine protease inhibitors and cytotoxic T lymphocytes. Immunol Rev 2010; 235:147158.
  • 22
    Belaaouaj A, McCarthy R, Baumann M, Gao Z, Ley TJ, Abraham SN, Shapiro SD: Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis. Nat Med 1998; 4:615618.
  • 23
    Heutinck KM, ten Berge IJ, Hack CE, Hamann J, Rowshani AT: Serine proteases of the human immune system in health and disease. Mol Immunol 2010; 47:19431955.
  • 24
    Law RH, Zhang Q, McGowan S, Buckle AM, Silverman GA, Wong W, Rosado CJ, Langendorf CG, Pike RN, Bird PI, Whisstock JC: An overview of the serpin superfamily. Genome Biol 2006; 7:216.
  • 25
    Askew DJ, Silverman GA: Intracellular and extracellular serpins modulate lung disease. J Perinatol 2008; 28(Suppl 3):S127S135.
  • 26
    Kaseba-Sata C, Kasolo F, Ichiyama K, Mitarai S, Nishiyama A, Kanayama N, Wakasugi N: Increased risk of intrauterine transmission of HIV-1 associated with granulocyte elastase in endocervical mucus. J Acquir Immune Defic Syndr 2006; 41:249251.
  • 27
    Moriuchi H, Moriuchi M, Fauci AS: Cathepsin G, a neutrophil-derived serine protease, increases susceptibility of macrophages to acute human immunodeficiency virus type 1 infection. J Virol 2000; 74:68496855.
  • 28
    Chertov O, Ueda H, Xu LL, Tani K, Murphy WJ, Wang JM, Howard OM, Sayers TJ, Oppenheim JJ: Identification of human neutrophil-derived cathepsin G and azurocidin/CAP37 as chemoattractants for mononuclear cells and neutrophils. J Exp Med 1997; 186:739747.
  • 29
    Sambrano GR, Huang W, Faruqi T, Mahrus S, Craik C, Coughlin SR: Cathepsin G activates protease-activated receptor-4 in human platelets. J Biol Chem 2000; 275:68196823.
  • 30
    Wilson TJ, Nannuru KC, Singh RK: Cathepsin G recruits osteoclast precursors via proteolytic activation of protease-activated receptor-1. Cancer Res 2009; 69:31883195.
  • 31
    Blumenthal R, Dimitrov DS: Targeting the sticky fingers of HIV-1. Cell 2007; 129:243245.
  • 32
    Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F: Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell 2007; 129:263275.
  • 33
    Forssmann WG, The YH, Stoll M, Adermann K, Albrecht U, Tillmann HC, Barlos K, Busmann A, Canales-Mayordomo A, Gimenez-Gallego G, Hirsch J, Jimenez-Barbero J, Meyer-Olson D, Munch J, Perez-Castells J, Standker L, Kirchhoff F, Schmidt RE: Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide. Sci Transl Med 2010; 2:63re3.
  • 34
    Congote LF: The C-terminal 26-residue peptide of serpin A1 is an inhibitor of HIV-1. Biochem Biophys Res Commun 2006; 343:617622.
  • 35
    Whitney JB, Asmal M, Geiben-Lynn R: Serpin induced antiviral activity of prostaglandin synthetase-2 against HIV-1 replication. PLoS ONE 2011; 6:e18589.
  • 36
    Elmaleh DR, Brown NV, Geiben-Lynn R: Anti-viral activity of human antithrombin III. Int J Mol Med 2005; 16:191200.
  • 37
    Zhou X, Shapiro L, Fellingham G, Willardson BM, Burton GF: HIV replication in CD4 +  T lymphocytes in the presence and absence of follicular dendritic cells: inhibition of replication mediated by α-1-antitrypsin through altered IκBα ubiquitination. J Immunol 2011; 186:31483155.
  • 38
    Pott GB, Chan ED, Dinarello CA, Shapiro L: Alpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood. J Leukoc Biol 2009; 85:886895.
  • 39
    Janciauskiene S, Larsson S, Larsson P, Virtala R, Jansson L, Stevens T: Inhibition of lipopolysaccharide-mediated human monocyte activation, in vitro, by alpha1-antitrypsin. Biochem Biophys Res Commun 2004; 321:592600.
  • 40
    Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ, Reilly CS, Peterson ML, Schultz-Darken N, Brunner KG, Nephew KR, Pambuccian S, Lifson JD, Carlis JV, Haase AT: Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009; 458:10341038.
  • 41
    Shattock RJ, Moore JP: Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 2003; 1:2534.
  • 42
    Benarafa C, Priebe GP, Remold-O'Donnell E: The neutrophil serine protease inhibitor serpinb1 preserves lung defense functions in Pseudomonas aeruginosa infection. J Exp Med 2007; 204:19011909.
  • 43
    Smyth MJ, Trapani JA: Granzymes: exogenous proteinases that induce target cell apoptosis. Immunol Today 1995; 16:202206.
  • 44
    Hirst CE, Buzza MS, Bird CH, Warren HS, Cameron PU, Zhang M, Ashton-Rickardt PG, Bird PI: The intracellular granzyme B inhibitor, proteinase inhibitor 9, is up-regulated during accessory cell maturation and effector cell degranulation, and its overexpression enhances CTL potency. J Immunol 2003; 170:805815.
  • 45
    McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM: Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 1995; 96:456464.
  • 46
    Venkataraman N, Cole AL, Svoboda P, Pohl J, Cole AM: Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J Immunol 2005; 175:75607567.
  • 47
    Drannik AG, Henrick BM, Rosenthal KL: War and peace between WAP and HIV: role of SLPI, trappin-2, elafin and ps20 in susceptibility to HIV infection. Biochem Soc Trans 2011; 39:14271432.
  • 48
    Ghosh M, Shen Z, Fahey JV, Cu-Uvin S, Mayer K, Wira CR: Trappin-2/Elafin: a novel innate anti-human immunodeficiency virus-1 molecule of the human female reproductive tract. Immunology 2010; 129:207219.
  • 49
    Butler MW, Robertson I, Greene CM, O'Neill SJ, Taggart CC, McElvaney NG: Elafin prevents lipopolysaccharide-induced AP-1 and NF-kappaB activation via an effect on the ubiquitin-proteasome pathway. J Biol Chem 2006; 281:3473034735.
  • 50
    McNeely TB, Shugars DC, Rosendahl M, Tucker C, Eisenberg SP, Wahl SM: Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 1997; 90:11411149.
  • 51
    Ma G, Greenwell-Wild T, Lei K, Jin W, Swisher J, Hardegen N, Wild CT, Wahl SM: Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med 2004; 200:13371346.
  • 52
    Py B, Basmaciogullari S, Bouchet J, Zarka M, Moura IC, Benhamou M, Monteiro RC, Hocini H, Madrid R, Benichou S: The phospholipid scramblases 1 and 4 are cellular receptors for the secretory leukocyte protease inhibitor and interact with CD4 at the plasma membrane. PLoS ONE 2009; 4:e5006.
  • 53
    Turk V, Bode W: The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett 1991; 285:213219.
  • 54
    Creasy BM, McCoy KL: Cytokines regulate cysteine cathepsins during TLR responses. Cell Immunol 2011; 267:5666.
  • 55
    Suzuki T, Hashimoto S, Toyoda N, Nagai S, Yamazaki N, Dong HY, Sakai J, Yamashita T, Nukiwa T, Matsushima K: Comprehensive gene expression profile of LPS-stimulated human monocytes by SAGE. Blood 2000; 96:25842591.
  • 56
    Tamura T, Thotakura P, Tanaka TS, Ko MS, Ozato K: Identification of target genes and a unique cis element regulated by IRF-8 in developing macrophages. Blood 2005; 106:19381947.
  • 57
    Xu Y, Schnorrer P, Proietto A, Kowalski G, Febbraio MA, Archa-Orbea H, Dickins RA, Villadangos JA: IL-10 controls cystatin C synthesis and blood concentration in response to inflammation through regulation of IFN regulatory factor 8 expression. J Immunol 2011; 186:36663673.
  • 58
    Staun-Ram E, Miller A: Cathepsins (S and B) and their inhibitor Cystatin C in immune cells: modulation by interferon-β and role played in cell migration. J Neuroimmunol 2011; 232:200206.
  • 59
    Schnoeller C, Rausch S, Pillai S, Avagyan A, Wittig BM, Loddenkemper C, Hamann A, Hamelmann E, Lucius R, Hartmann S: A helminth immunomodulator reduces allergic and inflammatory responses by induction of IL-10-producing macrophages. J Immunol 2008; 180:42654272.
  • 60
    Verdot L, Lalmanach G, Vercruysse V, Hoebeke J, Gauthier F, Vray B: Cystatins up-regulate nitric oxide release from interferon-gamma-activated mouse peritoneal macrophages. J Biol Chem 1996; 271:2807728081.
  • 61
    Verdot L, Lalmanach G, Vercruysse V, Hoebeke J, Gauthier F, Vray B: Chicken cystatin stimulates nitric oxide release from interferon-gamma-activated mouse peritoneal macrophages via cytokine synthesis. Eur J Biochem 1999; 266:11111117.
  • 62
    Luciano-Montalvo C, Meléndez LM: Cystatin B associates with signal transducer and activator of transcription 1 in monocyte-derived and placental macrophages. Placenta 2009; 30:464467.
  • 63
    Chan Ed, Pott GB, Silkoff PE, Ralston AH, Bryan CL, Shapiro L: Alpha-1-antitrypsin inhibits nitric oxide production. J Leukoc Biol 2012; 92:12511260.
  • 64
    Al-Omari M, Korenbaum E, Ballmaier M, Lehmann U, Jonigk D, Manstein DJ, Welte T, Mahadeva R, Janciauskiene S: Acute-phase protein α1-antitrypsin inhibits neutrophil calpain I and induces random migration. Mol Med 2011; 17:865874.
  • 65
    Voltersvik P, Bostad L, Dyrhol-Riise AM, Eide GE, Rosok BI, Olofsson J, Asjo B: Cystatin A and HIV-1 p24 antigen expression in tonsillar lymphoid follicles during HIV-1 infection and during highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 41:277284.
  • 66
    Sokal DC, Karim QA, Sibeko S, Yende-Zuma N, Mansoor LE, Baxter C, Grobler A, Frolich J, Kharsany AB, Miya N, Mlisana K, Maarshalk S, Karim SS: Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial. Antivir Ther 2013; 18:301310.
  • 67
    Celum C, Baeten JM: Antiretroviral-based HIV-1 prevention: antiretroviral treatment and pre-exposure prophylaxis. Antivir Ther 2012; 17:14831493.
  • 68
    Morris GC, Lacey CJ: Microbicides and HIV prevention: lessons from the past, looking to the future. Curr Opin Infect Dis 2010; 23:5763.
  • 69
    Bahgat MM, Błazejewska P, Schughart K: Inhibition of lung serine proteases in mice: a potentially new approach to control influenza infection. Virol J 2011; 8:27.
  • 70
    Baudo F, Caimi TM, de Cataldo F, Ravizza A, Arlati S, Casella G, Carugo D, Palareti G, Legnani C, Ridolfi L, Rossi R, D'Angelo A, Crippa L, Giudici D, Gallioli G, Wolfler A, Calori G: Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med 1998; 24:336342.
  • 71
    Hay JW, Robin ED: Cost-effectiveness of alpha-1 antitrypsin replacement therapy in treatment of congenital chronic obstructive pulmonary disease. Am J Public Health 1991; 81:427433.
  • 72
    Asmal M, Whitney JB, Luedemann C, Luedemann C, Carville A, Steen R, Letvin NL, Geiben-Lynn R: In vivo anti-HIV activity of the heparin-activated serine protease inhibitor antithrombin III encapsulated in lymph-targeting immunoliposomes. PLoS ONE 2012; 7:e48234.
  • 73
    Buckheit RW, Watson KM, Morrow KM, Ham AS: Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Res 2010; 85:142158.